Live
Endpoints NewsKardigan readies Nasdaq IPO to back three cardio drugsFierceBiotechAs calls for COINS Act expansion grow, will new rules sweep up China biotech licensing?FierceBiotechOlympus pushes deeper into oncology with $270M BioProtect dealClinical OMICsHeart Attack Byproduct Linked to Brain Inflammation and Cognitive DeclineEndpoints NewsPost-Hoc Live: Jeremy Levin on biotech's existential momentEndpoints NewsOutlook says FDA will sign off on its version of Avastin for wet AMDBioWorldKennedy offers emergency immunity for use of MCM in hantavirusBioWorldAhR you ready for this? A new (or not-so-new) approach in UCBioWorldRegulatory actions for May 26, 2026BioWorldFinancings for May 26, 2026BioWorldIn the clinic for May 26, 2026BioWorldOther news to note for May 26, 2026
Illumina Apr 11, 2026

Is It Time To Reassess Illumina (ILMN) After Its 61.7% One Year Share Price Rebound - Yahoo Finance

Is It Time To Reassess Illumina (ILMN) After Its 61.7% One Year Share Price Rebound - Yahoo Finance

Original
Body unavailable. Use the original source.